sg it is just discussion about the state of the industry and I find it very useful. Prana is still very much a player in the AD space from what I have seen.
Notorious is a bit extreme. I thought the Reach2HD trial was a success, and as planned, that is the program moving forward towards phase3.
Biogen had a mid stage MS trial fail in June and the price plunged about $60, now it is way past the original price on what some think is very thin AD data. Once Prana get a trial underway PBT should recover a lot of lost value IMO.
Using similar science, page-20
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $7.879K | 2.590M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 58 | 79758033 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 1157860 | 1 |
View Market Depth
| Last trade - 15.57pm 17/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |